Yatsen’s big bet: Can science win consumers’ love?
Yatsen Global, known for its fast-beauty brand Perfect Diary, is shifting focus to R&D and clinical innovation to build consumer loyalty. CEO Jinfeng (David) Huang emphasizes consumer-centric innovation, with R&D expenses exceeding 3% of revenue. The company has invested over RMB 770 million in R&D since 2020 and expanded into high-margin skincare brands. Yatsen aims to balance scientific innovation with consumer needs to drive long-term growth.
How this was made

The 30-second read
Why it matters
The disclosed R&D figures provide the first quantitative glimpse into the company's strategic shift, offering a modest informational edge.
Market read
New R&D spending data may influence investor perception of Yatsen's growth trajectory and margin outlook.
What to watch
Potential regulatory hurdles in foreign markets and the time lag between patent filing and commercial product launch.
Background
Yatsen Global, known for the fast‑beauty brand Perfect Diary, is reallocating capital toward clinical R&D and patent development.
Market effects
Signals a broader move by fast‑beauty firms toward higher‑margin, science‑based skincare, potentially influencing peer valuations.
Highlights Chinese beauty firms' push into premium markets, may affect Asia‑Pacific consumer‑goods sentiment.
Adds to global narrative of beauty brands investing in R&D to differentiate beyond hype.
Counterpoint
The R&D spend could erode profitability without guaranteeing consumer adoption, making the pivot risky.
Key entities
- CompanyYatsen Global
Chinese beauty conglomerate transitioning to science‑driven skincare.
- ExecutiveJinfeng (David) Huang
Founder and CEO of Yatsen Global.



